Sign inJoin waitlistJoin the waitlist

Geoffrey Johnson

Physician · WinnMed

Credentials: · · · · · · · ·

History

WinnMed
2024–Present

Nuclear Radiology Mayo Clinic Health System Red Cedar Medical/SCU/RT Quality Care Committee
2015–2016
Nuclear Medicine
2012–2015
Diagnostic Radiology
Mayo Clinic College of Medicine and Science
2008–2012
Allergy and Immunology
Mayo Clinic College of Medicine and Science
2006–2008
Preliminary Internal Medicine
Mayo Clinic College of Medicine and Science
2005–2006
Mayo Clinic School of Medicine
2001–2005

Research

Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
Circulation · 2016 · 1,659 citations
Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4
The Journal of Immunology · 2002 · First of 4 authors · 511 citations
Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging: Predicting Survival for Patients With ATTR Cardiac Amyloidosis
JAMA Cardiology · 2016 · 347 citations

Ayse Kendi
22 papers
Daniel Childs
21 papers
Eugene Kwon
20 papers
Jacob Orme
20 papers · 2 as a fellow
Oliver Sartor
16 papers
Matt Thorpe
15 papers
Stephen Broski
14 papers · 7 as a resident
Derek Johnson
13 papers · 5 as a resident
PP
Patrick Peller
13 papers
Annie Packard
11 papers
Christopher Hunt
11 papers
BB
Brian Burkett
10 papers · 6 as a fellow

Clinical trials

68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer
Principal investigator · Completed · Phase 3
Mayo Clinic
2022–2023
Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy
Principal investigator · Completed · Phase 1
Perspective Therapeutics
2021–2022
64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
Site PI · Recruiting · Phase 1, Phase 2
Clarity Pharmaceuticals Ltd
2021–2026
MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
Sub-investigator · Recruiting · Phase 1, Phase 2
Perspective Therapeutics
2023–2029